Nurix Therapeutics, Inc.
NASDAQ:NRIX
19.2 (USD) • At close February 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 109.997 | 54.627 | 64.474 | 80.506 | 119.356 | 34.816 | 25.591 |
| Short Term Investments
| 499.586 | 233.281 | 244.667 | 215.214 | 161.792 | 2.904 | 13.448 |
| Cash and Short Term Investments
| 609.583 | 287.908 | 309.141 | 295.72 | 281.148 | 37.72 | 39.039 |
| Net Receivables
| 0 | 0 | 0 | 6.204 | 11.346 | 0 | 0 |
| Inventory
| 0 | 0 | -1.1 | 0 | 0 | 0 | 0 |
| Other Current Assets
| 9.804 | 7.595 | 9.308 | 9.398 | 5.94 | 1.634 | 1.615 |
| Total Current Assets
| 619.387 | 295.503 | 318.449 | 311.118 | 298.434 | 39.354 | 40.654 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 45.896 | 47.95 | 29.508 | 25.345 | 6.672 | 3.871 | 4.422 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | -3.301 | -3.326 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 7.421 | 63.879 | 137.189 | 90.89 | 0.506 | 0.17 |
| Tax Assets
| 0 | 0 | 3.301 | 3.326 | 0 | 0 | 0 |
| Other Non-Current Assets
| 4.06 | 4.724 | 4.923 | 3.119 | 0.347 | 0.317 | 0.151 |
| Total Non-Current Assets
| 49.956 | 60.095 | 98.31 | 165.653 | 97.909 | 4.694 | 4.743 |
| Total Assets
| 669.343 | 355.598 | 416.759 | 476.771 | 396.343 | 44.048 | 45.397 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 11.482 | 6.401 | 5.064 | 6.65 | 3.412 | 1.598 | 1.297 |
| Short Term Debt
| 8.014 | 13.906 | 11.06 | 7.694 | 0 | 0 | 0 |
| Tax Payables
| 1.237 | 0.03 | 0.085 | 0.075 | 0.074 | 0 | 0 |
| Deferred Revenue
| 38.364 | 48.098 | 37.633 | 41.212 | 32.799 | 9.612 | 28.42 |
| Other Current Liabilities
| 36.757 | 24.94 | 16.813 | 10.627 | 8.254 | 4.927 | 3.115 |
| Total Current Liabilities
| 95.854 | 86.958 | 70.655 | 66.258 | 44.539 | 16.137 | 32.832 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 20.289 | 23.125 | 6.434 | 9.189 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 45.022 | 35.974 | 59.022 | 60.685 | 35.693 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 3.301 | 3.326 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 26.207 | 0 | 0 | 0 | 0.85 | 49.932 | 49.412 |
| Total Non-Current Liabilities
| 46.496 | 68.147 | 42.408 | 68.211 | 61.535 | 85.625 | 49.412 |
| Total Liabilities
| 142.35 | 155.105 | 113.063 | 134.469 | 106.074 | 101.762 | 82.244 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 396.343 | 48.195 | 48.195 |
| Common Stock
| 0.076 | 0.049 | 0.047 | 0.045 | 0.039 | 0.004 | 0.003 |
| Retained Earnings
| -738.769 | -545.2 | -401.252 | -220.892 | -103.698 | -60.456 | -38.757 |
| Accumulated Other Comprehensive Income/Loss
| 0.15 | -0.655 | -4.319 | -0.608 | 0.087 | -0.002 | -0.004 |
| Other Total Stockholders Equity
| 1,265.536 | 746.299 | 709.22 | 563.757 | 393.841 | -48.188 | -48.188 |
| Total Shareholders Equity
| 526.993 | 200.493 | 303.696 | 342.302 | 290.269 | -57.714 | -36.847 |
| Total Equity
| 526.993 | 200.493 | 303.696 | 342.302 | 290.269 | -57.714 | -36.847 |
| Total Liabilities & Shareholders Equity
| 669.343 | 355.598 | 416.759 | 476.771 | 396.343 | 44.048 | 45.397 |